N/A N=7 Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease
Chronic Rhinosinusitis · Aspirin Exacerbated Respiratory Disease · Asthma
Primary: Urinary Levels of Cys-Leukotrienes — 874.05; 771.99 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
Asthma, Aspirin-Induced · Aspirin Exacerbated Asthma
Primary: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo — 79; 139 mg
Phase 2 N=54 Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Asthma, Aspirin-Induced
Primary: Change From Baseline in Sinonasal Outcome Test-22 Score — -6.7; -13.7 units on a scale
Phase 2 N=36 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Nasal Polyps · Asthma, Aspirin-Induced · Aspirin-exacerbated Respiratory Disease
Primary: Provocative Dose 2 (PD2) During Aspirin Challenge — 121; 142 mg
Phase 2 N=19 Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
Aspirin Exacerbated Respiratory Disease (AERD)
Primary: Proportion of Patients Who Experience a ≥ 20% Decrease in Forced Expiratory Volume in One Second (FEV1) Compared to Baseline Following a Dose of Investigational…
Phase 4 N=95 Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Asthma, Aspirin-Induced · Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score — -14.09; -4.37 points
Phase 2 N=54 Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
Lung Carcinoma · Tobacco Use Disorder
Primary: Changes in Smoking-related Gene Expression Signature Score in Nasal Epithelium — -1.11; 1.39 gene expression signature score — p=0.04
Phase 2 N=63 Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Tobacco Use Disorder
Primary: Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers — -0.15; 0.26 score on a scale
Early Phase 1 N=48 GSNOR Phenotyping/GSNO Challenge in Severe Asthma
Asthma
Primary: FeNO — 14.3; 34.3; 36.0; 49 parts per billion — p=<0.1
Phase 2 N=15 Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
Early Phase 1 N=92 Aspirin Resistance in Coronary Artery Disease
Coronary Artery Disease
Primary: Change in Serum Thromboxane B2 — 5.02; 2.78 ng/mL — p=0.005
N/A N=132 Genotypic and Phenotypic Correlates of Resistance to Aspirin
Platelet Dysfunction Due to Aspirin
Primary: Whole Blood Coagulation — 453.8 Aspirin response units (ARU)
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 2 N=15 Anti-Platelets in Chronic Obstructive Pulmonary Disease
COPD · Emphysema · Emphysema or COPD
Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84
Phase 2 N=24 Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Chronic Rhinosinusitis (Diagnosis) · Nasal Polyps · Eosinophilia
Primary: Change in Nasal Polyp Score — .9; .3 score on a scale
N/A N=4 Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects
Healthy
Primary: Change in Exhaled Inflammatory Mediator Levels — 1.42 pg/mL
N/A N=38 Eosinophilic Airway Inflammation and Mepolizumab
Asthma
Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…
Early Phase 1 N=9 In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
Phase 4 N=13 Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
Aspirin Sensitivity
Primary: Number of Participants Without Respiratory Reaction During Aspirin Desensitization — 0; 5 Participants — p=0.036
Phase 1 N=16 Early Airway Response to Allergen in Asthmatics (MK-0000-176)
Asthma
Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001
N/A N=362 Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)
Asthma
Primary: Change in Asthma Control Test Score — 3.32 change in composite score
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
Phase 2 N=400 LIPS-A: Lung Injury Prevention Study With Aspirin
Acute Respiratory Distress Syndrome
Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53
N/A N=12 Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells
Asthma
Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05
N/A N=120 Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Churg-Strauss Syndrome · Eosinophilic Asthma · Eosinophilic Esophagitis
Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants
N/A N=15 Aspirin Responsiveness in Women With Coronary Artery Disease
CAD
Primary: Women With Known CAD Who Are Hyporesponsive to Low Dose (81 mg) Aspirin — 0 participants
N/A N=42 Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants Who Responded — 7; 4 participants
N/A N=225 Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)
Asthma
Primary: Exhaled Nitric Oxide at Baseline and Over the Observational Period — 15.1; 9.9; 13.7; 8.6 parts per billion
N/A N=38 Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose
Allergic Airway Disease
Primary: Total Nasal Cell Count in Response to DEP Challenge at 0, 6 and 24 hr With or Without BSE Intervention — 4.44; 4.50; 4.73; 4.70 log cells/mL — p=<0.001
Phase 3 N=92 Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)
Asthma
Primary: Juniper Asthma Control Questionnaire (ACQ) Results — -0.15; -0.38 units on a scale